NCT05995418 · RECRUITING
Study on the Health Economic Burden of Alzheimer's Disease in China
This is an observational study — no drug, device, or treatment involved. Researchers in China are tracking the real-world financial and quality-of-life costs that Alzheimer's places on patients and their families. They want to understand how much the disease actually costs, and how it affects daily wellbeing. There is no intervention being tested. Think of it as a large survey and records review, not a clinical experiment.
Eligibility criteria
Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD. 2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction. 4.Participants or their legal representatives sign informed consent. Exclusion criteria 1. History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2). 2. Presence of mental or neurological developmental delay. 3. Presence of other known conditions that may cause cognitive impairment. 4. Diagnosis of a disease that prevents completion of cognitive assessments. 5. Refusal to sign informed consent at baseline.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-06-05